Andrei COLITA

Latest posts by Andrei COLITA (see all)

Present and Future in Treatment of Hodgkin Lymphoma - July 19, 2019
Onset Risk Factors and Treatment Response Features of Refractory Hodgkin Lymphoma - July 2, 2015
Ibrutinib, a Novel Agent in Relapsed or Refractory Chronic Lymphocytic Leukemia - June 22, 2015

Articles signed on MÆDICA, JCM:

Present and Future in Treatment of Hodgkin Lymphoma

MÆDICA - a Journal of Clinical Medicine | Vol. 14, No. 2, 2019

Andrei TURBATU, Andrei COLITA, Ana-Maria BORDEA, Madalina OPREA, Cecilia GHIMICI, Ionel GELATU, Loredana Alina GHIMFUS, Andra Georgiana STOICA, Cristina Elena BANU and Anca-Roxana LUPU

ABSTRACT

Hodgkin lymphoma is a highly curable malignant hemopathy, using chemotherapy, radiotherapy, target therapies and hematopoietic stem cell transplantation. Current research in this field focuses on identifying prognostic factors associated with the pathogenic characteristics of the tumoral process, enabling the therapy to be adjusted to each patient’s degree of risk.
The identification of biomarkers associated with the tumoral process is extremely important because these molecules can be targets for new biological therapies.
Keywords: Hodgkin lymphoma, tumoral microenvironment, treatment, innovative therapy

Full text | PDF

Onset Risk Factors and Treatment Response Features of Refractory Hodgkin Lymphoma

Oana STANCA, Anca Mariana CIOBAN, Anca Roxana LUPU, Cecilia GHIMICI, Irina TRIANTAFYLLIDIS, Andrei COLITA and Ileana Delia MUT

ABSTRACT

Background: The International Prognostic Factors Project on Advanced Hodgkin lymphoma (HL) developed a seven factor prognostic score consisting of gender, age, stage, serum albumin, hemoglobin, leukocytosis and lymphocytopenia for the newly diagnosed Hodgkin disease patients in advanced stages, who receive chemotherapy.

Objectives: The purpose of this study was to determine whether this prognostic score would also be useful for refractory Hodgkin lymphoma patients in monitoring response to treatment.

Material and method: In the period 2000-2012, we performed a study on a group of 91 patients to show that the prognostic factors identified by the International Prognostic Factors (IPF) score affect the event- free survival (EFS) and the overall survival (OS). Our study also intends to show that the results of these factors change with the treatment response in patients with HL included in the category of patients with refractory disease.

Results: B symptoms, onset lymph node, more than 3 areas involved, bulky disease, extranodal involvement, low serum albumin, erythrocytes sedimentation rate (ESR), C reactive protein (CRP), lactic dehydrogenase (LDH) and anemia were associated with poorer EFS and OS. Male gender, stage, histological type, age (>45 years) and leukocytosis were not associated with significantly poorer outcomes.

Conclusions: the prognostic score for advanced disease is also useful in predicting relapse in patients with HL and early detection of response in patients with refractory HL.

Keywords: Follicular lymphoma, diagnosis, prognosis

Full text | PDF

Ibrutinib, a Novel Agent in Relapsed or Refractory Chronic Lymphocytic Leukemia

Ana-Maria IVANESCU, Madalina OPREA, Andrei TURBATU, Andrei COLITA and Anca Roxana LUPU

ABSTRACT

Refractory or relapsed chronic lymphocytic leukemia is still a hematologic malignancy with an unfavorable evolution after several lines of chemotherapy, even when associated with immunotherapy.

The additional presence of adverse prognostic factors such as17p deletion, 11 q deletion, unmutated IgVH genes, CD 38 and ZAP 70 expression further limits therapeutic possibilities.

Over the past two years numerous studies have focused on finding new therapeutic options useful in cases of relapsed or refractory chronic lymphocytic leukemia.

Ibrutinib is a new agent that has shown efficacy in treating these cases, the benefits of response and survival rate having been obtained using Ibrutinib as monotherapy, as well as in combination with immunotherapy or chemotherapy

Full text | PDF

Composite Diffuse Large B-Cell Lymphoma and Follicular B-Cell Lymphoma – Case Report and Review of Literature

Andrei TURBATU, Marilena STOIAN, Iulian BREZEAN, Victor Constantin Ion STOICA, Andrei COLITA, Camelia DOBREA, Nicoleta STATE, Cosmin IONESCU, Ana-Maria IVANESCU, Madalina OPREA, Cecilia GHIMICI and Anca Roxana LUPU

ABSTRACT

Composite lymphoma refers to the co-occurrence of two or more morphologically and immunophenotypically separate lymphomas in the same topographic site at the time of clinical presentation. It is an infrequent type of lymphoid neoplasm, present in lymphoid tissue and may be due to the existence of two genetically related neoplasms such as transformation of a single lymphoma into another more aggressive lymphoma or be due to the presence of two clonally unrelated lymphomas. This paper is presenting a case of diffuse non-Hodgkin large B-cell lymphoma with areas of low grade and high grade follicular non-Hodgkin B-cell lymphoma in a retroperitoneal lymph node and spleen of an 62 year old woman. Histopathological examination and immunohistochemistry features proved the diagnosis of composite lymphoma.

Full text | PDF

Author archives

Andrei COLITA

Latest posts by Andrei COLITA (see all)

Articles signed on MÆDICA, JCM:

Present and Future in Treatment of Hodgkin Lymphoma

SELECT ISSUE

Members Area